Neoadjuvant radiotherapy dose escalation for locally advanced rectal cancers in the new era of radiotherapy: A review of literature.
Image-guided radiotherapy
Intensity-modulated radiotherapy
Neoadjuvant radiotherapy
Radiotherapy
Rectal cancer
Volumetric Modulated Arc Therapy
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
26 Oct 2021
26 Oct 2021
Historique:
received:
14
04
2021
revised:
27
06
2021
accepted:
14
09
2021
entrez:
17
11
2021
pubmed:
18
11
2021
medline:
18
11
2021
Statut:
ppublish
Résumé
The standard treatment of locally advanced rectal cancers (LARC) consists on neoadjuvant chemoradiotherapy followed by total mesorectal excision. Different data in literature showed a benefit on tumor downstaging and pathological complete response (pCR) rate using radiotherapy dose escalation, however there is shortage of studies regarding dose escalation using the innovative techniques for LARC (T3-4 or N1-2). To analyze the role of neoadjuvant radiotherapy dose escalation for LARC using innovative radiotherapy techniques. In December 2020, we conducted a comprehensive literature search of the following electronic databases: PubMed, Web of Science, Scopus and Cochrane library. The limit period of research included articles published from January 2009 to December 2020. Screening by title and abstract was carried out to identify only studies using radiation doses equivalent dose 2 Gy fraction (EQD2) ≥ 54 Gy and Volumetric Modulated Arc Therapy (VMAT), intensity-modulated radiotherapy or image-guided radiotherapy (IGRT) techniques. The authors' searches generated a total of 2287 results and, according to PRISMA Group (2009) screening process, 21 publications fulfil selection criteria and were included for the review. The main radiotherapy technique used consisted in VMAT and IGRT modality. The mainly dose prescription was 55 Gy to high risk volume and 45 Gy as prophylactic volume in 25 fractions given with simultaneous integrated boosts technique (42.85%). The mean pCR was 28.2% with no correlation between dose prescribed and response rates ( Dose escalation neoadjuvant radiotherapy using innovative techniques is safe for LARC achieving higher rates of pCR. EQD2 doses > 58.9 Gy is associated with higher rate of surgical complications.
Sections du résumé
BACKGROUND
BACKGROUND
The standard treatment of locally advanced rectal cancers (LARC) consists on neoadjuvant chemoradiotherapy followed by total mesorectal excision. Different data in literature showed a benefit on tumor downstaging and pathological complete response (pCR) rate using radiotherapy dose escalation, however there is shortage of studies regarding dose escalation using the innovative techniques for LARC (T3-4 or N1-2).
AIM
OBJECTIVE
To analyze the role of neoadjuvant radiotherapy dose escalation for LARC using innovative radiotherapy techniques.
METHODS
METHODS
In December 2020, we conducted a comprehensive literature search of the following electronic databases: PubMed, Web of Science, Scopus and Cochrane library. The limit period of research included articles published from January 2009 to December 2020. Screening by title and abstract was carried out to identify only studies using radiation doses equivalent dose 2 Gy fraction (EQD2) ≥ 54 Gy and Volumetric Modulated Arc Therapy (VMAT), intensity-modulated radiotherapy or image-guided radiotherapy (IGRT) techniques. The authors' searches generated a total of 2287 results and, according to PRISMA Group (2009) screening process, 21 publications fulfil selection criteria and were included for the review.
RESULTS
RESULTS
The main radiotherapy technique used consisted in VMAT and IGRT modality. The mainly dose prescription was 55 Gy to high risk volume and 45 Gy as prophylactic volume in 25 fractions given with simultaneous integrated boosts technique (42.85%). The mean pCR was 28.2% with no correlation between dose prescribed and response rates (
CONCLUSION
CONCLUSIONS
Dose escalation neoadjuvant radiotherapy using innovative techniques is safe for LARC achieving higher rates of pCR. EQD2 doses > 58.9 Gy is associated with higher rate of surgical complications.
Identifiants
pubmed: 34786390
doi: 10.12998/wjcc.v9.i30.9077
pmc: PMC8567526
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9077-9089Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Références
Technol Cancer Res Treat. 2019 Jan 1;18:1533033818824367
pubmed: 30803368
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
Am J Surg. 1995 Dec;170(6):609-12; discussion 612-3
pubmed: 7492011
Br J Radiol. 2017 May;90(1073):20160667
pubmed: 28256898
Dis Colon Rectum. 2002 Mar;45(3):305-13; discussion 313-5
pubmed: 12068185
Turk J Med Sci. 2019 Oct 24;49(5):1484-1489
pubmed: 31651118
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):67-72
pubmed: 23790770
Radiother Oncol. 2014 Jan;110(1):155-9
pubmed: 24239243
Radiat Oncol. 2019 Nov 29;14(1):215
pubmed: 31783766
Br J Surg. 2012 Jul;99(7):918-28
pubmed: 22362002
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
Clin Oncol (R Coll Radiol). 2021 Jan;33(1):e1-e14
pubmed: 32669228
Ann Surg Oncol. 2012 Sep;19(9):2822-32
pubmed: 22434243
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):169-75
pubmed: 8083110
Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):110-8
pubmed: 25015203
Cancer Manag Res. 2019 Feb 15;11:1579-1586
pubmed: 30863168
Ann Surg. 2016 Mar;263(3):458-64
pubmed: 24263329
Clin Transl Radiat Oncol. 2019 Apr 12;18:80-86
pubmed: 31341981
Strahlenther Onkol. 2014 Jun;190(6):515-20
pubmed: 24715243
J Gastrointest Cancer. 2018 Jul 14;:
pubmed: 30006679
Ann Surg. 2019 Nov;270(5):747-754
pubmed: 31634178
J Clin Oncol. 2016 Sep 20;34(27):3300-7
pubmed: 27480145
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):146-158
pubmed: 29254769
Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):883-8
pubmed: 10705009
Lancet Oncol. 2015 Aug;16(8):979-89
pubmed: 26189067
Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):1008-1018
pubmed: 32565319
Anticancer Res. 2016 Aug;36(8):4081-7
pubmed: 27466517
Radiother Oncol. 2014 Oct;113(1):1-9
pubmed: 25281582
Clin Transl Oncol. 2017 Aug;19(8):969-975
pubmed: 28194687
Clin Transl Oncol. 2017 Feb;19(2):189-196
pubmed: 27271749
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):752-60
pubmed: 15936556
Radiat Oncol. 2017 Sep 21;12(1):156
pubmed: 28934968
Radiat Oncol. 2017 Aug 22;12(1):139
pubmed: 28830475
Oncotarget. 2016 Feb 2;7(5):6345-51
pubmed: 26621840
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):461-5
pubmed: 16226396
Radiat Oncol. 2014 Mar 07;9:70
pubmed: 24606870
Br J Surg. 2019 Sep;106(10):1298-1310
pubmed: 31216064
Adv Radiat Oncol. 2017 Apr 12;2(3):455-464
pubmed: 29114614
Ann Coloproctol. 2019 Apr;35(2):83-93
pubmed: 31113173
Ann Ital Chir. 2003 Sep-Oct;74(5):555-8
pubmed: 15139712
Radiol Med. 2020 Oct;125(10):990-998
pubmed: 32277332
N Engl J Med. 1997 Apr 3;336(14):980-7
pubmed: 9091798
ANZ J Surg. 2005 May;75(5):286-91
pubmed: 15932438
J Cancer. 2017 Sep 6;8(16):3114-3121
pubmed: 29158782
J Cancer. 2020 Mar 15;11(12):3536-3542
pubmed: 32284749
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Lancet Oncol. 2015 Aug;16(8):919-27
pubmed: 26156652
Radiother Oncol. 2019 May;134:110-118
pubmed: 31005204
Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1389-93
pubmed: 17394942
Am J Clin Oncol. 2006 Oct;29(5):435-41
pubmed: 17023775